Présentation
Contact
Marina Cavazzana est pédiatre, professeur d'hématologie depuis 2000, directrice du département de biothérapie de l'hôpital Necker, Université Paris Descartes. Elle est Directrice du Centre d'Investigation Clinique en Biothérapie (Inserm/Assistance Publique - Hôpitaux de Paris) et membre du laboratoire de recherche de Lymphohématopoïèse Humaine à l'institut Imagine.
Ses principaux axes de recherche et cliniques sont le développement du système immunitaire hématopoïétique et la thérapie cellulaire et génique pour les maladies héréditaires et acquises du système hématopoïétique. Son groupe étudie les moyens d'améliorer les résultats cliniques de la transplantation de cellules souches hématopoïétiques, le franchissement des barrières HLA et la différenciation des cellules souches murines et humaines vers les lignées lymphocytaires. Elle a lancé plusieurs essais cliniques basés sur l'utilisation de cellules souches hématopoïétiques modifiées in vivo pour traiter des patients atteints de troubles héréditaires, dont les résultats cliniques sont encourageants. Elle est l'auteur ou co-auteur de plusieurs brevets et de plus de 250 publications dans des revues à comité de lecture. Marina Cavazzana a reçu 2 ERC (2011 et 2016) et un financement de l'Etat dans le cadre du programme Investissements d’Avenir (PIA) de l'Agence Nationale de la Recherche (ANR) (Recherche Hospitalo-Universitaire en santé) (2019).
Son travail a été récompensé par l'American Society of Hematology (Award on Clinical Research in Gene Therapy en 1999), par l'Académie Française des sciences (Special Medical Award en 2000 et Jean-Pierre Lecocq Award on Gene Therapy en 2004). Elle a reçu le titre d'Officier de l'Ordre National de la Légion d'honneur en 2011, et a reçu le prix Irène Joliot Curie 2012 «Femmes scientifiques de l'année» (Académie des sciences et ministère de l'Éducation et de la Recherche). Elle a également été récompensée par l'Académie nationale de médecine en 2016 et a reçu le prix Ernest Beutler en 2017 (American Society of Hematology). Elle a également été élue membre international de la National Academy of Medicine en 2019.
Ressources & publications
-
2017Journal (source)Stem Cells DevGene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point ...
-
Journal (source)Mol Ther Methods Clin DevSuccessful Preclinical Development of Gene Therapy for Recombinase-Activating...
-
Journal (source)Mol Ther Methods Clin DevBiosafety Studies of a Clinically Applicable Lentiviral Vector for the Gene T...
-
2018Journal (source)Front ImmunolDisease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-K...
-
2019Journal (source)Blood AdvBaboon envelope LVs efficiently transduced human adult, fetal, and progenitor...
-
2021Journal (source)BloodA combination of cyclophosphamide and interleukin-2 allows CD4+ T cells conve...
-
2017Journal (source)BloodReticular dysgenesis: international survey on clinical presentation, transpla...
-
2015Journal (source)J Allergy Clin ImmunolAn in vivo genetic reversion highlights the crucial role of Myb-Like, SWIRM, ...
-
2014Journal (source)J Allergy Clin ImmunolThe BLNK adaptor protein has a nonredundant role in human B-cell differentiat...
-
2014Journal (source)J Allergy Clin ImmunolSuccessful RAG1-SCID gene therapy depends on the level of RAG1 expression.
-
2014Journal (source)J Allergy Clin ImmunolRecombination-activating gene 1 (Rag1)-deficient mice with severe combined im...
-
2019Journal (source)Bone Marrow TransplantEx vivo generated human T-lymphoid progenitors as a tool to accelerate immune...
-
2018Journal (source)Front ImmunolDisease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-K...
-
2015Journal (source)JAMAOutcomes following gene therapy in patients with severe Wiskott-Aldrich syndr...
-
2020Journal (source)Am J TransplantDonor-targeted serotherapy as a rescue therapy for steroid-resistant acute GV...
-
2021Journal (source)Nat ImmunolSingle-cell analysis of FOXP3 deficiencies in humans and mice unmasks intrins...
-
2021Journal (source)Cell Mol ImmunolA DL-4- and TNFα-based culture system to generate high numbers of nonmodified...
-
2021Journal (source)Nat CommunTransient mTOR inhibition rescues 4-1BB CAR-Tregs from tonic signal-induced d...
-
2022Journal (source)Nat MedLong-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: t...
-
2022Journal (source)Nat CommunBase-editing-mediated dissection of a γ-globin cis-regulatory element for the...
-
2023Journal (source)Mol Ther Nucleic AcidsNovel lentiviral vectors for gene therapy of sickle cell disease combining ge...
-
Journal (source)Annu Rev Genomics Hum GenetSickle Cell Disease: From Genetics to Curative Approaches.
-
2023Journal (source)BloodAdenine base editor-mediated correction of the common and severe IVS1-110 (G>...
-
2022Journal (source)Mol TherCombination of lentiviral and genome editing technologies for the treatment o...
-
2018Journal (source)HaematologicaMutations in the adaptor-binding domain and associated linker region of p110δ...
-
2019Journal (source)HaematologicaExtensive multilineage analysis in patients with mixed chimerism after alloge...
-
2019Journal (source)BloodLentiviral and genome-editing strategies for the treatment of β-hemoglobinopa...
-
2019Journal (source)Hum. Mol. Genet.Gene therapy of hemoglobinopathies: progress and future challenges.
-
2019Journal (source)Nat Rev Drug DiscovGene therapy targeting haematopoietic stem cells for inherited diseases: prog...
-
Journal (source)Mol Ther Methods Clin DevA Nontoxic Transduction Enhancer Enables Highly Efficient Lentiviral Transduc...
-
2019Journal (source)HaematologicaPlerixafor enables safe, rapid, efficient mobilization of hematopoietic stem ...
-
Journal (source)J. Allergy Clin. Immunol.Generation of adult human T-cell progenitors for immunotherapeutic applications.
-
2016Journal (source)Hum. Gene Ther.Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
-
2017Journal (source)Stem Cells Dev.Gene Therapy with Hematopoietic Stem Cells: The Diseased Bone Marrow's Point ...
-
2018Journal (source)BloodGene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict...
-
2019Journal (source)J. Clin. Invest.Loss of ARHGEF1 causes a human primary antibody deficiency.
-
2019Journal (source)Blood AdvGene transfer into hematopoietic stem cells reduces HLH manifestations in a m...
-
Journal (source)J. Allergy Clin. Immunol. 2017Clinical and immunologic phenotype associated with activated phosphoinositide...
-
2015Journal (source)J. Clin. Invest.A human immunodeficiency caused by mutations in the PIK3R1 gene.
-
Journal (source)J. Allergy Clin. Immunol.X-linked primary immunodeficiency associated with hemizygous mutations in the...
-
2019Journal (source)Blood AdvGene transfer into hematopoietic stem cells reduces HLH manifestations in a m...
-
2016Journal (source)Cell Death DisAK2 deficiency compromises the mitochondrial energy metabolism required for d...
-
2013Journal (source)Stem CellsHuman T-lymphoid progenitors generated in a feeder-cell-free Delta-like-4 cul...
-
2020Journal (source)BloodClonal tracking in gene therapy patients reveals a diversity of human hematop...
-
2020Journal (source)HaematologicaA gain-of-function RAC2 mutation is associated with bone-marrow hypoplasia an...
-
2020Journal (source)BloodClonal tracking in gene therapy patients reveals a diversity of human hematop...
-
2020Journal (source)J ImmunolSeletalisib for Activated PI3Kδ Syndromes: Open-Label Phase 1b and Extension ...